Abstract:Introduction: Hyperactivation of the EGFR/RAS pathway is a major driver of tumorigenesis and metastasis. It has been difficult to design effective therapies contravening the compensatory EGFR/RAS downstream effector pathways to achieve curative antitumor efficacy. Seven in absentia homologues (SIAH1 and SIAH2) are RING-domain E3 ubiquitin ligases that function as the most downstream signaling gatekeeper of the EGFR/RAS pathway. Our prior studies demonstrated that SIAH inhibition led to tumor eradication of multiple malignant human cancers cell lines in xenograft models. We propose that SIAH is a major tumor vulnerability/actionable drug target for inhibiting persistent EGFR/RAS pathway activation; we aim to elucidate the molecular mechanisms underpinning antitumor efficacy of our SIAH inhibitor. Methods: Reverse phase protein arrays (RPPAs) in conjunction with Principal Component Analysis (PCA) were used to quantify fold-changes of 300 proteins/phospho-proteins that were significantly up- or down-regulated in response to SIAH inhibition (p < 0.001). Independent RPPA assays were performed in triplicate on doxycycline (DOX)-inducible MiaPaCa, MDA-MB-231, MDA-MB-468, HeLa, and A459 cell lines in which our SIAH inhibitor, SIAH2 PD, expression was induced by a Tet-ON/OFF system. Four experimental conditions were used: Tet-ON control cells without DOX (group A) and with DOX induction (group B), Tet-ON-SIAH2 PD cancer cells without DOX (no SIAH2 PD inhibitor expression in group C) and with DOX induction (SIAH2 PD inhibitor expression in group D). The ratios of D/C/B/A, D/C, D/B, C/A, and B/A were calculated in a pairwise comparison after normalization to GAPDH as an internal control. To validate identified targets of interest, immunoblotting of biological quadruplicate cell lysates for each respective cell line were performed for group C and D at 3-, 5-, and 7-days post DOX induction; target proteins' expression normalized to β-actin, α-Tubulin, or GAPDH respectively, and the pathway alterations induced by SIAH2 inhibition were standardized, quantified, and analyzed. Results: RPPA analyses identified 6 proteins (NFκB, Caspase-7, PARP, Cofilin, PD-L1, and Collagens) exhibiting differential expression in response to SIAH2 blockade. Western blot analyses independently confirmed their altered expression patterns, further supporting their roles as the biological readout of SIAH2 loss-of-function in human cancer cells. Conclusion: The RPPA-based cancer pathway mapping provides valuable molecular insight into the antitumor efficacy and reveals a major tumor vulnerability in human cancer pathway/network rewiring when SIAH2 is blocked in late-stage malignant cells. The kinomic data support our innovative strategy to design anti-SIAH-based anti-EGFR/RAS target therapies to control and eradicate undruggable and incurable human cancers in the future. Citation Format: Jonathan M. Baker, Andrew Howell, Ashleigh Hannah, Julia Wulfkuhle, Natalie Stahr, Rosa Gallagher, Emanuel Petricoin, Amy Tang. Investigating mechanisms of tumor eradication by blocking SIAH E3 ligase, a major tumor vulnerability, in EGFR/RAS-driven human cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1841.

SIAH3 is frequently epigenetically silenced in cancer and regulates mitochondrial metabolism

Aberrant DNA Methylation Associated with Silencing BNIP3 Gene Expression in Haematopoietic Tumours

SIRT3 is a Mitochondria-Localized Tumor Suppressor Required for Maintenance of Mitochondrial Integrity and Metabolism During Stress.

SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer

Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies

Cancer SLC43A2 alters T cell methionine metabolism and histone methylation

Regulation of the SIAH2-HIF-1 Axis by Protein Kinases and Its Implication in Cancer Therapy

Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies*

Abstract 6864: Tumor suppressor function of the ubiquitin ligase Siah1a in melanoma is mediated by myeloid derived suppressor cells

Sirt3 is a tumor suppressor in lung adenocarcinoma cells.

Sirt3 Is A Mitochondrial Tumor Suppressor: A Scientific Tale That Connects Aberrant Cellular Ros, The Warburg Effect, And Carcinogenesis

SIRT3 Protein Deacetylates Isocitrate Dehydrogenase 2 (IDH2) and Regulates Mitochondrial Redox Status

Protein Disulfide Isomerase Family A Member 3 Knockout Abrogate Effects of Vitamin D on Cellular Respiration and Glycolysis in Squamous Cell Carcinoma

The SIAH2-NRF1 axis spatially regulates tumor microenvironment remodeling for tumor progression

Histones Methyltransferase NSD3 Inhibits Lung Adenocarcinoma Glycolysis Through Interacting with PPP1CB to Decrease STAT3 Signaling Pathway

Phylogenetic analysis of the SINA/SIAH ubiquitin E3 ligase family in Metazoa

Downregulation of Siah1 Promotes Colorectal Cancer Cell Proliferation and Migration by Regulating AKT and YAP Ubiquitylation and Proteasome Degradation.

Siah3 acts as a physiological mitophagy suppressor that facilitates axonal degeneration

Histone H3Y99sulf regulates hepatocellular carcinoma responding to hypoxia

Abstract 1841: Investigating mechanisms of tumor eradication by blocking SIAH E3 ligase, a major tumor vulnerability, in EGFR/RAS-driven human cancer

Methylation of hypoxia-inducible factor 3 subunit alpha contributes to poor prognosis in lung adenocarcinoma